Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2020-04-03 Transaction in Own Shar…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
03-04-20-NL.pdf
Transaction in Own Shares Classification · 100% confidence The document is titled "Verwerving en vervreemding van eigen aandelen" (Acquisition and disposal of own shares) and details transactions where UCB NV bought back its own shares (Aandelen Inkoopprogramma 2020) and disposed of shares related to employee incentive plans (LTI plans). This activity directly relates to the company managing its own stock holdings, which falls under the definition of 'Transaction in Own Shares'. The document provides specific transaction dates, quantities, and prices, confirming it is a report of the activity itself, not just an announcement of a report. Therefore, the appropriate code is POS.
2020-04-03 Dutch
special report board.pdf
Governance Information Classification · 95% confidence The document is explicitly titled "SPECIAL REPORT BY THE BOARD OF DIRECTORS TO THE SHAREHOLDERS on the use and purpose of the authorized capital prepared in accordance with article 7:199 of the Belgian Code of Companies and Associations". This document details the proposal to renew the Board's powers regarding authorized capital, which directly relates to the issuance of shares, convertible bonds, or warrants. This subject matter falls under corporate governance and capital structure management, specifically concerning shareholder authorization for capital changes. While it discusses capital structure, it is a formal report presented to shareholders for approval regarding future capital actions, making it distinct from a simple Capital/Financing Update (CAP) or Share Issue (SHA). It is a detailed report concerning governance over capital, which aligns closely with Governance Information (CGR) or a specific type of shareholder communication. Given the focus on the legal framework (BCCA) and the proposal to renew powers for capital increases, it is a governance document related to capital structure. However, none of the definitions perfectly capture a 'Special Report on Authorized Capital Renewal'. Since it is a formal report detailing governance rules for capital changes presented to shareholders, it is best classified as Governance Information (CGR), as it dictates how the company's capital structure can be managed by the Board, or potentially a specialized report that might fall under Regulatory Filings (RNS) if CGR is too broad. Reviewing the definitions, CGR covers "internal rules, board structure, and governance practices." The renewal of authorized capital powers is a fundamental governance practice regarding capital. It is a comprehensive report, not a short announcement, so RPA/RNS fallback is less likely unless CGR is inappropriate. I will classify it as CGR due to its focus on the rules and powers granted to the Board concerning capital structure, which is a core governance topic.
2020-03-27 English
rapport special conseil.pdf
Capital/Financing Update Classification · 98% confidence The document is titled "RAPPORT SPÉCIAL DU CONSEIL D'ADMINISTRATION AUX ACTIONNAIRES concernant l'utilisation du capital autorisé et les objectifs poursuivis établi en application de l'article 7:199 du Code des sociétés et associations" (Special Report of the Board of Directors to Shareholders concerning the use of authorized capital and the objectives pursued established pursuant to Article 7:199 of the Companies and Associations Code). This document explicitly discusses the proposal to renew the Board's authority to increase the company's capital (capital autorisé) and outlines the circumstances and objectives for using this power, which is a matter directly related to the company's capital structure and financing flexibility. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP), as it is a detailed report seeking shareholder approval for future financing mechanisms, rather than a general announcement of a completed financing deal (CAP) or a general shareholder meeting material (AGM-R, although it is presented to an EGM). Since it details the structure and limits of capital authorization, it is best classified as a specific financing/capital structure document.
2020-03-27 French
bijzonder verslag rvb.pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled "BIJZONDER VERSLAG VAN DE RAAD VAN BESTUUR AAN DE AANDEELHOUDERS over het gebruik en de nagestreefde doeleinden van het toegestane kapitaal" (Special Report of the Board of Directors to the Shareholders on the use and intended purposes of the authorized capital). It explicitly discusses the renewal of the Board's authorization to increase capital, referencing specific articles of the Belgian Companies and Associations Code (WVV) and detailing the terms (5% or 10% increases, shareholder rights, etc.). This document is a formal report prepared for a shareholder meeting (Extraordinary General Meeting scheduled for April 30, 2020) to explain a proposed resolution regarding capital structure management. This aligns perfectly with the description of a document related to capital structure changes and shareholder approval, fitting best under 'Capital/Financing Update' (CAP) or potentially 'Proxy Solicitation & Information Statement' (PSI) given its context for an upcoming EGM. However, since the core subject is the authorization for capital increases and the structure thereof, CAP is the most precise fit among the options, as it deals directly with financing mechanisms and capital structure, which is the subject of the report being presented to shareholders for approval. It is a detailed report, not just a brief announcement (RPA/RNS).
2020-03-27 Dutch
20200324 UCB Share Repurchase Program 2020_ENG final.pdf
Transaction in Own Shares Classification · 100% confidence The document explicitly announces the launch of a 'Share Repurchase Program 2020' where UCB intends to acquire up to 1.2 million of its own shares. This action directly relates to the company buying back its own stock. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS), which covers share repurchases. The document is a press release announcing this specific corporate action.
2020-03-24 English
20200324 - UCB Programme de rachat d'actions propres 2020_FR Final.pdf
Transaction in Own Shares Classification · 100% confidence The document is a press release dated March 24, 2020, announcing the launch of a 'Programme de rachat d'actions propres' (Share Buyback Program) to cover employee long-term incentive plans. The key action described is the company acquiring its own ordinary shares, up to a maximum of 1.2 million shares. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs. Although it is a press release, the core subject matter is the transaction itself, making POS a more specific fit than the general RPA or RNS categories.
2020-03-24 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.